Pulse Biosciences (PLSE) ties COO stock awards to $5B value, revenue goals
Rhea-AI Filing Summary
PULSE BIOSCIENCES, INC. (PLSE) reported that Chief Operating Officer Liane Rae Teplitsky received equity awards on August 8, 2026. She was granted 200,000 Restricted Stock Units, each representing one share of common stock, and 700,000 stock options with an exercise price of $19.06 per share. The RSUs vest upon performance-based criteria set by the board. Two sevenths of the option shares vest in equal installments on each of the first four anniversaries of the grant date, with the remainder vesting upon achieving performance targets tied to company market capitalization and GAAP product revenue, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Teplitsky Liane Rae
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units F1, F2 | 200,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (right to buy) F3 | 700,000 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 200,000 shares (Direct);
Stock Option (right to buy) — 700,000 shares (Direct)
Footnotes (3)
- F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's common stock.
- F2. The RSUs will vest upon certain performance-based criteria established by the Board of Directors.
- F3. Two sevenths of the shares subject to the option will vest in equal installments on the first, second, third, and fourth anniversaries of the grant date and the remaining shares subject to the option will vest in equal tranches upon the achievement of three performance-based vesting criteria tied to both the Issuer's market capitalization ranging from $2 billion to $5 billion and GAAP product revenue targets ranging from $100 million to $330 million, in all cases, subject to the Reporting Person's continued service through each vesting milestone.
Key Figures
RSUs granted: 200,000 Restricted Stock Units
RSU holdings after grant: 200,000 Restricted Stock Units
Stock options granted: 700,000 options
+5 more
8 metrics
RSUs granted
200,000 Restricted Stock Units
Grant to COO on August 8, 2026; each RSU equals one share of common stock
RSU holdings after grant
200,000 Restricted Stock Units
Total RSUs reported as held directly following the August 8, 2026 grant
Stock options granted
700,000 options
Stock Option (right to buy) grant to COO on August 8, 2026
Option exercise price
$19.06 per share
Exercise price for 700,000 stock options granted on August 8, 2026
Option expiration date
August 8, 2036
Expiration date of the 700,000 stock options granted to the COO
RSU expiration date
August 8, 2033
Expiration date associated with the 200,000 RSUs granted
Market capitalization targets
$2 billion to $5 billion
Performance-based vesting criteria range for certain option tranches
GAAP product revenue targets
$100 million to $330 million
Performance-based vesting criteria range for certain option tranches
Key Terms
Restricted Stock Units, contingent right, performance-based criteria, market capitalization, +1 more
5 terms
Restricted Stock Units financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"each RSU represents a contingent right to receive one share of Issuer's"
performance-based criteria financial
"The RSUs will vest upon certain performance-based criteria established"
market capitalization financial
"criteria tied to both the Issuer's market capitalization ranging from $2"
Market capitalization is the total market value of a company’s outstanding shares, calculated by multiplying the current share price by the number of shares issued. It gives a quick snapshot of a company’s size and how investors value it, influencing perceived risk, index membership, and roughly how much it might cost to buy the whole company — like using a sticker price to compare the relative size and price of different houses.
GAAP product revenue financial
"and GAAP product revenue targets ranging from $100 million to $330"
FAQ
What equity awards did PLSE grant to COO Liane Rae Teplitsky on August 8, 2026?
She received 200,000 Restricted Stock Units and 700,000 stock options, each tied to shares of Pulse Biosciences common stock, with the options carrying a $19.06 exercise price and both awards subject to vesting conditions.
How do the 200,000 RSUs granted by PLSE to the COO vest?
The 200,000 RSUs vest upon achievement of performance-based criteria established by Pulse Biosciences’ Board of Directors, providing a contingent right to receive one share of common stock for each vested RSU.
What are the key terms of the 700,000 PLSE stock options granted to the COO?
The COO received 700,000 stock options with a $19.06 exercise price, expiring on August 8, 2036. Two sevenths vest in equal installments on the first four anniversaries of grant, with remaining tranches vesting upon specified performance criteria.
What performance metrics affect vesting of the PLSE stock options granted on August 8, 2026?
The remaining option tranches vest upon meeting performance criteria tied to Pulse Biosciences’ market capitalization between $2 billion and $5 billion and GAAP product revenue targets between $100 million and $330 million, subject to the COO’s continued service.
Are the new PLSE equity awards to the COO directly reported as buys or sells of common stock?
No. The filing reports grants of RSUs and stock options (acquisitions of derivative securities), not open-market purchases or sales of Pulse Biosciences common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
